Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to CELC. [ FAQ on what and how to ask] For non-CELC questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 2800 Campus Drive, Suite 140, Minneapolis, MN, United States, 55441
Employees: 155
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Co-Founder, Chairman & CEO
Co-Founder, Chief Science Officer, VP, Secretary & Director
Chief Financial Officer
Head of Investor Relations & Corporate Communications
General Counsel & Chief Compliance Officer
Acting Head of Clinical Operations
Chief Medical Officer
Chief Commercial Officer
Chief Strategy Officer
My Watchlist
